Marketing Collaboration on Protopic® Ointment for Treatment of Atopic Dermatitis in Japan

Maruho Co., Ltd. （Headquarters: Osaka, President & CEO: Koichi Takagi, hereafter referred to “Maruho”) and Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori, hereafter referred to “Astellas”) announced that the companies have agreed that Astellas will assign detailing/promotional activities for Protopic ®(generic name: tacrolimus hydrate) in Japan to Maruho on April 1, 2011 and thereafter will transfer its distribution right in Japan to Maruho on April 1, 2014. In contrast, Astellas will maintain the approval of manufacturing and distribution for Protopic® in Japan. The companies are committed to promote appropriate use of Protopic® ointment, and aim to realize the improvement of Quality of Life of more patients suffering from atopic dermatitis, through delivering Protopic® ointment. * Protopic® ointment shall mean Protopic® ointment 0.1% and Protopic® ointment 0.03% for pediatric. ####### Marketing Collaboration on Protopic® Ointment for Treatment of Atopic Dermatitis in Japan (pdf 79KB) Contact the Media Relations team Communications & Investor Relations Main phone line for Media: ＋81-3244-3201 Business hours (JST) From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm (closed on Saturdays, Sundays, national holidays and company holidays

The release as fetched from its publisher. astellas.com ↗